SAFETY EVALUATION OF SEQUENTIAL MITOMYCIN AND BACILLUS CALMETTE-GUERIN TREATMENT VERSUS BACILLUS CALMETTE-GUERIN MONOTHERAPY IN PATIENTS WITH HIGH RISK NON-MUSCLE INVASIVE BLADDER CANCER: MITOBCG STUDY(EUDRACT NUMBER 2017-004540-37)PRELIMINARY RESULT
Abstract
INTRODUCTION AND OBJECTIVE:
Aim of our study was to evaluate safety of sequential Mitomycin and Bacillus Calmette-Guérin (BCG) treatment versus BCG monotherapy in patients with High risk Non-Muscle Invasive Bladder Cancer.